<DOC>
	<DOCNO>NCT03056729</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability single-ascending intravenous ( IV ) infusion BIIB076 healthy volunteer participant Alzheimer 's disease ( AD ) . A secondary objective study healthy volunteer participant AD ass serum pharmacokinetic ( ) ( PK ) profile BIIB076 single-dose administration . Another secondary objective evaluate immunogenicity BIIB076 serum single-dose administration .</brief_summary>
	<brief_title>Single-Ascending-Dose Study BIIB076 Healthy Volunteers Participants With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Key Inclusion Criteria Healthy Participants Must good health determine Investigator , base medical history Screening evaluation . Key Inclusion Criteria Participants Alzheimer 's Disease ( AD ) Must clinical diagnosis mild AD consistent follow : Probable AD , accord National Institute Aging Alzheimer 's Association workgroups diagnostic guideline AD criterion [ McKhann 2011 ] . CSF concentration AÎ²42 ttau consistent diagnosis AD . Must MiniMental State Examination score 20 26 ( inclusive ) Screening . Key Exclusion Criteria Healthy Participants Brain MRI perform Screening show show evidence acute subacute hemorrhage , prior macrohemorrhage , cortical infract , &gt; 1 lacunar infarct , history diffuse whitematter disease finding , opinion Investigator , might contribute cause participant 's dementia , might pose risk participant , might prevent satisfactory MRI assessment safety monitoring . History clinically significant cardiac , endocrine , gastrointestinal , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal disease , major disease , determine Investigator . Current enrollment drug , biologic , device , clinical study treatment investigational drug approve therapy investigational use within 30 day ( 6 month biologics ) 5 halflives , whichever longer , prior Day1 . Contraindications brain MRI ( e.g. , pacemaker ; MRIincompatible aneurysm clip , artificial heart valve , metal foreign body ; claustrophobia medically manage ) . Contraindications Lumbar Puncture ( LP ) . Key Exclusion Criteria Participants Alzheimer 's Disease ( AD ) Any medical neurologic/neurodegenerative condition ( AD ) , opinion Investigator , might contribute cause participant 's cognitive impairment ( e.g. , substance abuse , vitamin B12 deficiency , abnormal thyroid function , stroke cerebrovascular condition , Lewy body dementia , front temporal dementia , head trauma ) . Clinically significant psychiatric illness ( e.g. , uncontrolled major depression , schizophrenia , bipolar affective disorder ) within 6 month prior Screening . History clinically significant cardiac , endocrine , gastrointestinal , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , renal disease , major disease , determine Investigator . Current enrollment drug , biologic , device , clinical study treatment investigational drug approve therapy investigational use within 30 day ( 6 month biologics ) 5 halflives , whichever longer , prior Day1 . Contraindications brain MRI ( e.g. , pacemaker ; MRIincompatible aneurysm clip , artificial heart valve , metal foreign body ; claustrophobia medically manage ) . Contraindications LP . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>